The US Food and Drug Administration (FDA) has approved Aprecia Pharmaceuticals Company's Spritam (levetiracetam) for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.

A mammal communication research conducted by the University of Sussex suggests that, like humans, horses use muscles underlying various facial features including their nostrils, lips and eyes to alter their facial expressions in a variety of social situations. The research is published in PLOS ONE.

The European Commission (EC) has approved under the European Union (EU) Merger Regulation the Pfizer Inc's pending acquisition of Hospira, Inc. The Commission's decision includes Pfizer’s commitment to divest certain assets.

The team from Washington University School of Medicine, St. Louis, has warned that people who have undergone bariatric surgery may be at the risk of getting drunk faster as the procedure drastically lowers body tolerance for alcohol. The paper is appeared in the journal JAMA Surgery.

Taro Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Keveyis™ (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.^[1] Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.^[2]